Economic burden of multiple sclerosis to the social insurance system in Germany
ConclusionThis study delivered important information regarding the economic burden of MS for the social insurance system in Germany. The top-down process of data collection yielded population-based results on the cost of illness.
This study aimed to investigate the in vitro effects of the Apigenin 3-Acetate on Th17 cells of MS patients and compare its efficacy with Apigenin and Methyl Prednisolone Acetate.IC50 for Apigenin 3-Acetate, and Methyl Prednisolone Acetate were determined using three healthy volunteers. The peripheral blood mononuclear cells (PBMCs) of five MS patients were isolated and co-cultured with a selected dose of Apigenin, Apigenin 3-Acetate, and Methyl Prednisolone Acetate for 48 hr, and then theproliferation of Th17 cells in isolated PBMCs was assessed by flow cytometry. The levels of RAR-related orphan receptor (RORC) and IL-17...
Conditions: Multiple Sclerosis; Neurologic Symptoms; Menstrual Cycle Interventions: Other: Position Sense; Other: Balance; Other: Dual Task Performance Sponsor: Ankara Yildirim Beyazıt University Completed
Condition: Spastic Parapareses Intervention: Device: Transcutaneous Spinal Direct Current Stimulation Sponsor: Lebanese American University Not yet recruiting
Condition: Multiple Sclerosis Intervention: Sponsors: BeCare Link LLC; Yale University Enrolling by invitation
Background: Patients with multiple sclerosis (MS) experience progressive thinning in optical coherence tomography (OCT) measures of neuroaxonal structure regardless of optic neuritis history. Few prospective studies have investigated the effects of disease-modifying therapies on neuroaxonal degeneration in the retina. Alemtuzumab is a monoclonal antibody shown to be superior to interferon β-1a in treating relapsing–remitting MS (RRMS). The purpose of this study was to assess the effects of alemtuzumab and first-line injectable treatments on OCT measures of neuroaxonal structure including peripapillary retinal ...
Publication date: Available online 27 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Tuba Rashid Khan, Cynthia Wang
Publication date: Available online 26 February 2020Source: NeuroImage: ClinicalAuthor(s): J.A. Kim, R.B. Bosma, K.S. Hemington, A. Rogachov, N.R. Osborne, J.C. Cheng, J. Oh, B.T. Dunkley, K.D. Davis
Publication date: Available online 26 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Paula Teixeira Marques, Cláudia Suemi Kamoi Kay, Flavia Machado Alves Basílio, Rosângela Lameira Pinheiro, Lineu Cesar Werneck, Paulo Jose Lorenzoni, Rosana Herminia Scola
(University of California - San Diego) An international team of scientists, led by UC San Diego researchers, has developed a new, multi-sensor tool that measures subtle changes in multiple sclerosis patients, allowing physicians to more frequently and more quickly respond to changes in symptoms or patient condition.
Nature Reviews Neurology, Published online: 26 February 2020; doi:10.1038/s41582-020-0329-3A new study has identified an association between socioeconomic status and the risk of disability in individuals with multiple sclerosis. The findings highlight the importance of collecting large, structured datasets for the study of modifiable risk factors.